Journal of Shanghai Jiao Tong University (Medical Science) ›› 2022, Vol. 42 ›› Issue (5): 680-684.doi: 10.3969/j.issn.1674-8115.2022.05.018

• Review • Previous Articles     Next Articles

Research progress in acquired cystic disease-associated renal cell carcinoma

XIANG Han1(), XIANG Wu2, ZHANG Weiguo1()   

  1. 1.Department of Radiology, Daping Hospital, Army Medical University, Chongqing 400042, China
    2.Department of Rehabilitation, Chongqing Beibei Traditional Chinese Medical Hospital, Chongqing 400799, China
  • Received:2022-01-17 Accepted:2022-04-18 Online:2022-05-28 Published:2022-05-28
  • Contact: ZHANG Weiguo;
  • Supported by:
    Fund of Chongqing Clinical Research Centre of Imaging and Nuclear Medicine(CSTC2015YFPT-gcjsyjzx0175)


Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is the most common type of RCC seen in patients with end-stage renal disease and acquired cystic kidney disease, and was added to the list of RCC subtypes in the 2016 World Health Organization classification. ACD-RCC is generally believed to be indolent, however, some tumors may show local recurrence and distant metastasis. Periodic screening should be performed in dialysis patients, especially in younger patients with minor comorbidities, early detection and early intervention can improve the prognosis and quality of life. Literatures published at home and abroad mainly focused on it's clinicopathological features, there is scarce research describing the imaging appearance, prognosis and surveillance of ACD-RCC. This paper summarizes the epidemiology, etiology, pathological features, imaging manifestations, treatment, prognosis and surveillance of ACD-RCC, and aims to provide a compressive understanding of the disease for clinicians.

Key words: acquired cystic disease, renal cell carcinoma, image features, prognosis

CLC Number: